Reportlinker Adds Trends in Health Technology Assessment

NEW YORK, June 14, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Trends in Health Technology Assessment

http://www.reportlinker.com/p0553308/Trends-in-Health-Technology-Assessment.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic

Introduction

The report explores approaches to HTA, profiles HTA organizations in six countries (Australia, Canada, France, Germany, the UK, and the US) and examines how their results are used to inform pricing and reimbursement decisions. The focus is on pharmaceuticals, medical devices, and diagnostics and how the rapidly evolving HTA environment will influence future market access of these technologies.

Features and benefits

* Analyze what evidence is required for HTA evaluations to show that a particular drug/medtech product represents an improvement on current practice.

* Gain an insight into HTA programs & identify common trends in assessment practices and areas where there are differences in processes and procedures.

* Evaluate how P&R policies are influenced by HTA outcomes and what impact HTA advice has on payors and providers, supported by case studies.

* Assess industry's role in providing evidence that meets diverse HTA demands.

* Evaluate how interaction between regulators and payors could pave the way for greater synergies between regulatory and HTA requirements.

Highlights

Clinical and cost effectiveness are assessed for pharmaceuticals in Australia, Canada and the UK, while clinical benefit is the main focus in France and Germany for new drugs. CER is rapidly gaining momentum in the US to inform federal funding decisions, while commercial US payors use clinical and economic evidence in formulary listings.

Patient input is gaining greater significance in HTA, helping to provide a broader perspective of a product's value in the real world setting. By February 2011, 22 drugs had benefited from the new process for patient group input during the Canadian Common Drug Review since it was introduced in May 2010.

From January 2011, the clinical benefit of all new pharmaceuticals launched in Germany must be assessed on the basis on manufacturers' dossiers. The Introduction of value-based pricing in the UK in 2014 will require all new brand medicines to demonstrate value, replacing the current system of selective appraisals by NICE.

Your key questions answered

* What factors are used by different HTA bodies to measure the costs and benefits of health technologies?

* How is advice provided by HTA organizations used by different payors?

* How can companies best approach the need to incorporate HTA requirements into their product development plans?

* What are the key challenges of HTA and what efforts are underway to address theses?

* Which organizations are involved in HTA in Australia, Canada, France, Germany, the UK, and the US?

Executive Summary

Overview of health technology assessment

National HTA organizations profiled

HTA in practice

Influence of HTA on pricing and reimbursement

Industry's role in HTA

Future perspectives

About the author

Disclaimer

Overview of health technology assessment

Summary

Introduction

Definition of HTA

HTA processes

Evolution of HTA

Collaborative initiatives

INAHTA

HTAi

EuroScan

EUnetHTA

Key HTA principles

Influence of HTA on pharma/medtech

National HTA organizations profiled

Summary

Introduction

Australia

PBAC

MSAC

PLAC

Canada

CADTH

Provincial HTA organizations

France

Pharmaceutical HTA

Medical device HTA

MTAs

Germany

G-BA

IQWiG

[email protected]

UK

NICE technology appraisals

Evaluation Pathway Program

NIHR HTA

US

CMS

AHRQ

PCORI

DERP

Private sector

HTA in practice

Summary

Introduction

Transparency

Stakeholder involvement

Patient input

Canada's new process for CDR

Calculating cost-effectiveness

NICE threshold

Theoretical thresholds

Cost minimization

Efficiency frontier

Cost-consequence analysis

Timeliness of HTA

Influence of HTA on pricing and reimbursement

Summary

Introduction

Uptake of HTA advice by payors

Australian government overrides PBAC advice

Listing of drugs assessed centrally in Canada

Dual recommendations in France

Pharmaceuticals

Medical devices

Reassessment

Germany's new early assessment procedure

HTA of older products

Implementation of advice by providers

Future role of NICE

Changing US landscape

CMS coverage of Provenge

Tackling uncertainty

US CED

Ontario's cancer drug scheme

UK patient access schemes

Managed entry in Australia

Industry's role in HTA

Summary

Introduction

European Tapestry Network

Swiss HTA consensus

Industry case study

Industry relationship with payors/policy-makers

Regulator/HTA/payor interaction

UK pilot parallel scientific advice process

Sweden's experience with parallel advice

US collaboration

Future perspectives

Summary

Introduction

Increased scope of HTA

Orphan drugs

HTA as part of product development

HTA and market access schemes

Convergence of HTA programs

EU HTA co-operation

Relative effectiveness/comparative effectiveness

Summary of conclusions

Appendix

Scope

Methodology

Secondary research

Glossary/Abbreviations

To order this report:

In Vitro Diagnostic Industry: Trends in Health Technology Assessment

In Vitro Diagnostic Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

CONTACT:
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.